SLC5A2 and diabetic kidney disease: Moreover, modulation of the Slc5a2 activity by inhibitors (SGLT2 inhibitors), which are promising drugs in the treatment of diabetes, including diabetic nephropathy (Vallon, 2011; Perkovic et al., 2019; Zelniker et al., 2019), may also modulate cyst growth in polycystic kidney diseases (Kapoor et al., 2015; Rodriguez et al., 2015; Patel and Dahl, 2021).